Skip to main content
Erschienen in: Reactions Weekly 1/2013

01.10.2013 | News item

Antimalarial's label updated to warn of visual impairment, sometimes permanent

Erschienen in: Reactions Weekly | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Excerpt

The Australian TGA is alerting healthcare professionals to new information added to the label of Lariam [mefloquine] regarding the potentially associated risk of eye disorders, including cataract, retinal disorders and damage to the optic nerve, occurring during treatment or up to several weeks after treatment. Symptoms of these eye disorders include visual impairment and blurred vision. In some cases patients have slowly recovered; however, there have also been reports of permanent damage.1
Fußnoten
1
See also Reactions 1471 p2; 803093461
 
Literatur
Zurück zum Zitat TGA - Therapeutic Goods Administration. Mefloquine hydrochloride (Lariam): Safety advisory -- potential for visual disturbances. Internet Document : 11 Oct 2013. Available from: URL: http://www.tga.gov.au TGA - Therapeutic Goods Administration. Mefloquine hydrochloride (Lariam): Safety advisory -- potential for visual disturbances. Internet Document : 11 Oct 2013. Available from: URL: http://​www.​tga.​gov.​au
Metadaten
Titel
Antimalarial's label updated to warn of visual impairment, sometimes permanent
Publikationsdatum
01.10.2013
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2013
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-013-6695-5

Weitere Artikel der Ausgabe 1/2013

Reactions Weekly 1/2013 Zur Ausgabe

Case report

Adenosine

Case report

Esomeprazole